Clinical Trial

Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Evaluating the efficacy and safety of treatment with Tislelizumab in combination with S-1 in patients with high-risk recurrent intrahepatic cholangiocarcinoma after radical surgery
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-10-27; most recent amendment 2025-01-09.
Trial Details
NCT Number NCT06664021
Lead Sponsor Anhui Provincial Hospital
Conditions Intrahepatic Cholangiocarcinoma
Enrollment 60 participants
Start Date 2024-11-16
Primary Completion 2026-12-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-01-10